Annual Secretraial Compliance Report for the financial year ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jenburkt Pharmaceuticals has filed its Annual Secretarial Compliance Report for FY2025-26, prepared by Nilesh Shah & Associates. The secretarial auditor found the company largely compliant with SEBI regulations but identified three technical deviations: (1) delayed financial result filings under Regulation 33 due to BSE queries requiring revised submissions for Q4 FY2025 and Q2 FY2026, (2) Audit Committee Chairperson Ms. Hina Mehta's absence from the July 2025 AGM due to being overseas, violating Regulation 18(1)(d), and (3) a prior-year shareholding pattern revision for Q1 FY2024. The company has been advised to ensure stricter compliance going forward and take utmost care while filing documents to avoid repeat submissions.
The non-compliances are procedural/administrative in nature rather than financial misconduct. No penalties were imposed. Shareholders should note that the company is generally well-governed but needs to improve its filing accuracy and board meeting attendance protocols to avoid regulatory queries.